Review article

Guidance on diagnosis, prevention and treatment of thromboembolic complications in COVID-19: a position paper of the Brazilian Society of Thrombosis and Hemostasis and the Thrombosis and Hemostasis Committee of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy

Fernanda Andrade Orsi a,⁎, Erich V. De Paula b, Fernanda de Oliveira Santos c,d, Marcelo Melzer Teruchkin e, Dirceu Hamilton Cordeiro Campêlo f, Tayana Teixeira Mello g, Maria Chiara Chindamo h,i, Ariane Vieira Scarlatelli Macedo j,k, Ana Thereza Rocha l,m, Eduardo Ramacciotti n,o,p, Ana Clara Kneese Nascimento q, Joyce Annichino-Bizzacchi b, Dayse Maria Lourenço , João Carlos de Campos Guerra f,r, Suely Meireles Rezende s, Cyriilo Cavalheiro Filho t,u

a Faculdade de Ciências Médicas da Universidade Estadual de Campinas (FCM-Unicamp), Campinas, SP, Brazil
b Centro de Hematologia e Hemoterapia da Universidade Estadual de Campinas (Hemocentro-Unicamp), Campinas, SP, Brazil
c AC Camargo Cancer Center, São Paulo, SP, Brazil
d Hospital 9 de Julho, São Paulo, SP, Brazil
e Laboratório de Doenças Vasculares do Hospital Moinhos de Vento, Porto Alegre, RS, Brazil
f Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
g Instituto de Hematologia, Hemostasia e Trombose (IHHT), Campinas, SP, Brazil
h Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
i Barra D’Or Hospital, Rede D’Or São Luiz, Rio de Janeiro, RJ, Brazil
j Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil
k Hospital São Luiz Jabaquara, São Paulo, SP, Brazil
l Escola Bahiana de Medicina e Saúde Pública, Salvador, BA, Brazil
m Faculdade de Medicina da Bahia da Universidade Federal da Bahia (FMB-UFBA), Salvador, BA, Brazil
n Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP), São Paulo, SP, Brazil
o Hospital Christãovã o da Gama, Grupo Leforte, Santo André, SP, Brazil
p Loyola University Medical Center, Maywood, IL, United States
q Universidade Federal de São Paulo (USP), São Paulo, SP, Brazil	r Centro de Hematologia de São Paulo (CHSP), São Paulo, SP, Brazil

⁎ Corresponding author at: Department of Clinical Pathology, Faculdade de Ciências Médicas da Universidade Estadual de Campinas (FCM-Unicamp), Rua Carlos Chagas 480, CEP 13083-970, Campinas, SP, Brazil.
E-mail address: ferorsi@unicamp.br (F.A. Orsi).
https://doi.org/10.1016/j.htct.2020.06.001
2531-1379/© 2020 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

In Uncontrolled COVID-19-associated death Moreover, hospitalization, that have been observed to happen due to a large number of Brocas and patients who have been diagnosed with COVID-19. In Brazil, COVID-19 had been diagnosed in more than 150,000 patients and caused more than 10,000 deaths by May 9, 2020, according to official data from the Brazilian Ministry of Health. During the COVID-19 outbreak in China, it was observed that approximately 80% of the patients had mild to moderate upper respiratory tract symptoms, 13.8% had severe disease (dyspnea, tachypnea, and hypoxia), which required hospitalization, and 6.1% developed critical symptoms (respiratory failure, septic shock or multiple organ dysfunction) that required treatment in an intensive care unit (ICU). Severe symptoms usually appeared after approximately 7–8 days from the onset of the disease and progression to critical COVID-19 usually occurred after the 11th day of symptoms.

The pathogenesis of COVID-19 is related to both the invasion of lung epithelial cells by SARS-CoV-2 and the host immune reaction against the virus. Uncontrolled systemic inflammatory response, resulting from the release of large amounts of pro-inflammatory cytokines is one of the hallmarks of the severe acute respiratory distress syndrome (ARDS) and multiple organ failure, the two main causes of death by COVID-19. Besides inflammation, COVID-19 patients may present with signs of hypercoagulability, characterized by pronounced elevation of fibrinogen levels and D-dimers, and may develop disseminated intravascular coagulation (DIC) at late stages of the disease. Increased D-dimer levels and the diagnosis of DIC are associated with a poor prognosis and death. Moreover, mounting evidence confirms that the incidence of arterial and venous thrombosis is increased in COVID-19 and that thrombotic events are associated with higher mortality. Therefore, the prevention of thrombosis is an essential part of the clinical management of these patients.

Overview of the evidence and use of this document

COVID-19 is a new disease with an unprecedented impact on public health. Accordingly, an impressive amount of information is being incorporated in the medical literature, with heterogeneous quality and unknown generalizability. At the same time, clinical dilemmas involving the management of patients increased the expectation of practicing physicians for guidance from trusted sources. COVID-19-associated hemostatic abnormalities and thrombotic risk are among the most discussed topics in medical care of these patients and have raised several questions regarding optimal clinical management.

Currently, due to the lack of high-quality studies and to the rapidly evolving literature, it is not possible to organize a formal medical guideline for these topics. However, we believe that providing the opinion of a panel of experts based on a careful and balanced review of the available evidence would be useful to the medical community in Brazil. Furthermore, healthcare in Brazil and available resources is rather heterogeneous and certainly differs from the reality in other countries, where other guidance papers are being published.
a panel of experts to discuss the current evidence available on the thromboprophylaxis and management of thrombotic events in patients with suspected COVID-19, in the sphere of healthcare in Brazil. The data discussed in this document was reviewed by May 9, 2020. Recommendations and suggestions reflect the opinion of the panel and should be reviewed periodically as new evidence emerges.

---

**Role of disseminated intravascular coagulopathy in COVID-19**

The host response to pathogens and sepsis involves the activation of multiple systems among which are innate immunity and hemostasis. Both systems have been shown to contribute to pathogen eradication by facilitating the access and the microbicidal function of phagocytes. However, deregulation and/or loss of local regulation of this so-called immunothrombotic response can lead to secondary damage mediated by thrombus formation. Accordingly, laboratory alterations consistent with the activation of hemostasis and fibrinolysis, such as increased levels of D-dimer, prolongation of the prothrombin time (PT), high fibrinogen levels, as well as consumption of platelets and fibrinogen in more severe cases, can be observed in the course of several infections and should be regarded as part of the host response to pathogens. This is particularly evident in COVID-19 patients, in whom increased D-dimer levels (which parallel the increase of IL-6) has been identified as an independent marker of severity. In fact, the association between increased D-dimer levels and poor prognosis has also been described in other forms of sepsis and pneumonia.

Of note, in a recent comparison of D-dimer levels between COVID-19 and non-COVID-19 pneumonia patients in China, similar levels were observed in both conditions. Similarly, the accumulation of fibrin in alveolar spaces and even the formation of microvascular thrombosis described in COVID-19, which has raised questions on whether anticoagulants should be used in higher doses in these patients, is also part of immunothrombosis and has been described in other forms of ARDS. Moreover, the use of several anticoagulant molecules was not capable of improving the outcome of sepsis in these patients.

Therefore, until the benefit of using therapeutic doses of anticoagulants in patients with COVID-19 based solely on D-dimer levels (i.e., in the absence of highly suspected or proven venous thromboembolism [VTE]) is demonstrated by randomized clinical trials, the use of anticoagulants in COVID-19 should be restricted to prophylaxis of VTE or the treatment of confirmed VTE events. These include deep venous thrombosis (DVT) (both symptomatic and asymptomatic, detected by screening methods), pulmonary embolism (PE) and catheter-associated thrombosis.

---

**Monitoring of coagulopathy**

Hypercoagulability in COVID-19 is characterized by increased levels of fibrinogen and D-dimers, prolonged PT and activated partial thromboplastin time (aPTT), mild thrombocytopenia (100–150 × 10^9/L), elevated levels of factor VIII (FVIII) and Von Willebrand factor (VWF). In addition, signs of DIC have been reported in late stages of severe COVID-19.

D-dimer levels are particularly high in critically ill patients in the ICU and among non-survivors, which suggests that D-dimer is a prognostic marker in COVID-19 and testing for it should be initially performed in all hospitalized patients. The association between increased D-dimers and severe COVID-19 may in part be explained by the above-mentioned interplay between inflammatory response and activation of coagulation. From that perspective, D-dimer levels can represent a surrogate marker for COVID-19 severity.

This is not novel, as some authors have used an elevated D-dimer as part of a scoring system to identify those at increased risk for VTE. Additionally, a recent Brazilian study showed that elevated D-dimer levels is common in viral infections in our country, such as Zika Virus and Chikungunya, which may be associated with an increase in the risk of thromboembolism. Lastly, D-dimers are elevated in the elderly, individuals with comorbidities, such as infection, inflammation, cancer, and the hospitalized patients. Nevertheless, to date, there is no validated cut-off value for D-dimer to guide changes in the management of anticoagulation in COVID-19 patients.

Therefore, considering the clinical impact of hypercoagulability in COVID-19, analysis of peripheral blood smear, platelet count, PT, aPTT, fibrinogen and D-dimer levels is recommended for all hospitalized patients. These parameters should be regularly monitored in critically ill patients. Increasing trends of D-dimer and other clinical variables, such as levels of oxygenation and ventilator parameters and possibly imaging studies, whenever feasible, must be jointly considered toward the suspicion of thrombotic events and the need for full anticoagulation. The most adequate time interval between tests is uncertain and testing should be based on clinical indication, assays availability and the local laboratory capacity and facilities.

---

**Systematic venous thromboembolism assessment**

The reported in-hospital cumulative incidence of VTE in COVID-19 patients ranges from 8 to 69%, with the highest incidence among patients in the ICU. Discrepancies in VTE incidence among studies can be attributed to differences in population, disease severity, strategies of thromboprophylaxis and practices regarding the performance of imaging tests. It is noteworthy that about half of the VTE patients were asymptomatic in one cohort from the Netherlands and the highest incidence of VTE (69%) was reported by a French study in which systematic ultrasounds were performed.

Based on concerns of the increased risk of VTE and the importance of early VTE detection, some experts and medical societies have recommended screening for DVT in COVID-19 patients in the ICU at admission and every 4–5 days thereafter. In this context, duplex scan is the imaging test of choice because it is easy to perform and almost risk-free. Furthermore, it can be performed at bedside, without the need to remove the patient from the ICU. Special attention should be
given to avoid exposure of the medical team while performing the tests and to prevent unnecessary transport of more severe patients out of the isolation units.

Thus, we suggest performing venous compression Duplex scan in ICU patients at admission and then at regular intervals (ideally every 4–5 days), whenever available or guided by clinical suspicion, to detect DVT and to prevent its complications. We also suggest maintaining vigilance for clinical and echocardiographic signs of PE, given that PE seems to be more frequent than DVT in COVID-19 patients. Routine screening for VTE in hospitalized patients with COVID-19, solely based on elevated D-Dimer, cannot be recommended at this point.

**Prophylaxis of venous thromboembolism**

**Indication of thromboprophylaxis**

Risk-assessment of VTE is recommended for all surgical and medical patients admitted to a hospital and those with acute respiratory and infectious diseases are at high risk of hospital-associated VTE, according to international guidelines. Several Brazilian hospitals have implemented systematic VTE risk-assessment protocols to the routine medical care as part of quality improvement measures and different VTE risk-assessment tools are available, such as IMPROVE score, the Brazilian Guideline for VTE Prophylaxis, the Caprini score and the Padua score.

However, the risk of hospital-associated VTE seems to be higher in hospitalized patients with COVID-19 than in other medical patients. It was demonstrated that 40% of patients hospitalized for COVID-19 (407/1026) present with a high Padua score (greater than or equal to 4) upon admission and without thromboprophylaxis a great proportion of patients may develop VTE, as shown in a Chinese cohort of severe COVID-19 pneumonia in which 25% of the patients had DVT of the lower limbs during hospitalization. These observations suggest that the risk for thrombosis in COVID-19 is a result not only of respiratory distress and acute infectious disease, but also of the disease associated coagulopathy.

Despite the highest risk of thrombosis being reported among patients in the ICU, a high incidence of VTE has also been observed in those admitted to general wards. The reported cumulative incidence of VTE in patients with COVID-19 during hospitalization in general wards ranges from 6% to 9%, of which half of the thrombotic events have been diagnosed in the first 24 h of hospitalization and 56% of the patients were not receiving thromboprophylaxis. Moreover, VTE was independently associated with death (hazard ratio (HR) of death, adjusted for age, sex and ICU stay, 2.4; 95% CI, 1.02–5.5) in a Dutch cohort.

Therefore, we recommend that all patients hospitalized for suspected or confirmed COVID-19 should receive pharmacologic thromboprophylaxis, in the absence of absolute contraindications. We suggest the use of low molecular weight heparin (LMWH) due to the ease of use and once daily dosing regimen. Alternatively, unfractionated heparin (UFH) or fondaparinux (particularly for patients with heparin-induced thrombocytopenia) can be given for thromboprophylaxis. In case a pharmacologic thromboprophylaxis is contraindicated, mechanical prophylaxis should be used as an alternative. Table 1 contains the contraindications for pharmacologic thromboprophylaxis in hospitalized medical patients.

**Dose of anticoagulation for prophylaxis**

Among severe COVID-19 patients admitted to ICU, the cumulative incidence of in-hospital thrombotic events ranges from 40 to 60%, despite the use of pharmacologic thromboprophylaxis. The most frequently diagnosed thrombotic complication has been PE. The dosing regimens that have been proposed are enoxaparin 40 mg twice daily, enoxaparin 1 mg/kg daily, therapeutic doses of LMWH (type of LMWH is not specified), nadroparin 5700 IU daily, and nadroparin 2850 IU twice daily (body weight < 100 kg). Of note, thrombotic events were also diagnosed in patients who were already receiving intermediate or therapeutic doses of LMWH. Middeldorp et al. further reported that the risk of VTE in ICU patients with COVID-19 was similar in the period when the standard dose of nadroparin prophylaxis was doubled (58%) in comparison with the period when standard prophylaxis was used (41%). Although thrombotic risk is high in severe COVID-19, possibly higher than in non–COVID-19 critically ill patients, there is no evidence to date supporting the increase of the dose of pharmacologic thromboprophylaxis to intermediate, nor therapeutic doses. Nevertheless, dose adjustments of LMWH and UFH for VTE prophylaxis have been suggested for obese surgical and medical patients and it may be reasonable to prescribe them for hospitalized obese patients with COVID-19.

There is also no evidence of factors associated with higher thrombotic risk to discriminate patients who would benefit from a different thromboprophylaxis approach. Furthermore,
Table 2 – Standard dose of LMWH, UFH and fondaparinux for prophylaxis and adjustments, according to body weight and renal function.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Standard dose</th>
<th>Body weight</th>
<th>Chronic kidney disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enoxaparin</td>
<td>40 mg SC daily</td>
<td>80–99 kg: 40–60 mg SC daily</td>
<td>CrCl 15–29 ml/min:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥ 100 kg: 80 mg SC daily</td>
<td>Give 50% of the dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Or adjustments based on BMI</td>
<td>CrCl &lt; 15 ml/min:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMI 30–40 kg/m²: 40–60 mg daily</td>
<td>contraindication; consider UFH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMI &gt; 40 kg/m²: 40 mg SC 12–12 h</td>
<td></td>
</tr>
<tr>
<td>Nadroparin</td>
<td>3800 UI SC daily</td>
<td>&gt;70 kg: 5700 UI SC daily</td>
<td>CrCl 30–50 ml/min:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Give 25% of the dose</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>5000 UI SC daily</td>
<td>100–139 kg: 7500 UI SC daily</td>
<td>CrCl &lt; 30 ml/min:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>140–180 kg: 5000 UI SC twice daily</td>
<td>contraindication; consider UFH</td>
</tr>
<tr>
<td>Bemiparin</td>
<td>3500 UI SC daily</td>
<td>&lt;60 kg: 2500 UI SC daily</td>
<td>CrCl = &lt;30 ml/min:</td>
</tr>
<tr>
<td>Tinzaparin</td>
<td>50 UI/kg/dia</td>
<td></td>
<td>Give 25% of the dose</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>2.5 mg SC daily</td>
<td></td>
<td>CrCl 20–29 ml/min:</td>
</tr>
<tr>
<td>UFH</td>
<td>5000 UI SC twice daily</td>
<td>BMI &gt; 30 kg/m²: 5000–7500 UI SC every 8 h</td>
<td>CrCl &lt; 20 ml/min:</td>
</tr>
</tbody>
</table>

LMWH: low molecular weight heparin; UFH: unfractionated heparin; BMI: body mass index; SC: subcutaneous; CrCl: creatinine clearance; IU: international unit.

autopsy studies demonstrated the predominance of microvascular thrombosis in the lungs, coincident with markers of inflammation, which is a hallmark of prolonged infection and sepsis.\(^{48,49}\) As mentioned above, anticoagulant treatment for sepsis has failed in multiple studies in the past.\(^{21,25–27}\)

Therefore, until further evidence of the benefit of increasing prophylactic doses emerges, we suggest the use of LMWH at standard dose for thromboprophylaxis, adjusted for body weight and renal function, in patients admitted to general wards or the ICU, unless there are specific contraindications. Table 2 contains the dosing regimens for VTE prophylaxis. We are aware that the apparent increased incidence of VTE in COVID-19 has led physicians to change their practice by increasing the dose of anticoagulation for prophylaxis to intermediate or therapeutic doses of LMWH in ICU patients or in patients with high D-dimers or fibrinogen levels. However, the benefit of this approach has not yet been confirmed and well-designed trials are needed to address this question.

**Duration of pharmacologic thromboprophylaxis**

Prior trials have demonstrated that thromboprophylaxis should be given to medically ill patients at high risk for thrombosis during the entire hospitalization period and for at least 6–14 days.\(^{50,51}\) Extended duration of pharmacologic thromboprophylaxis may benefit patients with persistent immobility after discharge or those with reduced mobility and additional risk factors for thrombosis, such as older age (above 75 years), previous history of VTE, known thrombophilia, active cancer, obesity, use of estrogen, or chronic heart or respiratory failure.\(^{52}\)

Although no specific studies on the duration of thromboprophylaxis in COVID-19 are available to date, thromboprophylaxis should be prescribed during the entire hospitalization period, unless there is a contraindication. Once there is a widespread pressure for early discharge of patients, another important consideration is to complete a minimum course of pharmacological thromboprophylaxis for at least 7 days.\(^{40}\)

Following this rationale, we suggest maintaining thromboprophylaxis after hospital discharge for COVID-19 patients who are at high risk for VTE or maintain immobility, unless there are specific contraindications. The risk and benefits of this approach should be reevaluated periodically.

**Diagnosis and treatment of venous thromboembolism**

DVT is suspected in case an edema, pain, redness or unilateral cyanosis of the limb is present. Suspicion of PE is based on clinical features, such as unexplained abrupt worsening in PaO\(_2\)/FiO\(_2\) and hemodynamic instability, or surrogate markers, such as pulmonary hypertension, abrupt right ventricular dilatation and hypokinesis or right heart thrombus in transit on echocardiography, increase in troponin or B-type natriuretic levels.\(^{53}\) Acute DVT and PE should be confirmed by imaging tests, ideally being ultrasound of the lower extremities and CT pulmonary angiography, respectively.
In the case an imaging test is not feasible due to difficulties in mobilizing or positioning the patient on mechanical ventilation for CT scans, the need to protect staff from exposure to COVID-19 patients or contraindications for the test, a presumptive diagnosis of acute VTE may be performed based on clinical history, combined with physical examination and laboratory or other available tests. Given that COVID-19 patients present with a significant elevation of D-dimers at baseline and there is no validated cut-off value to discriminate patients at high risk for VTE, the diagnosis of VTE should not be based solely on the values of D-dimers.

The treatment approach for acute thrombosis must be based on current guidelines. We recommend the use of LMWH for the treatment of acute VTE. Alternatively, UFH or fondaparinux can be used. Therapeutic doses of LMWH, UFH and fondaparinux are demonstrated in Table 3.

**Management of patients taking direct oral anticoagulants (DOAC) or vitamin K antagonist (AVK)**

In-hospital patients with severe COVID-19 are frequently treated with multiple drugs, including antiviral therapy which can strongly interact with DOACs. Given that DOACs and AVK interact with several drugs, it is highly recommended that doctors check for drug interaction before the prescription of any drug concomitantly with DOAC and AVK. In a cohort of severe COVID-19 inpatients taking DOACs and antiviral agents, Testa et al. have shown that DOAC plasma levels were 6 times higher during hospitalization, in comparison to the pre-hospitalization period. Therefore, we consider reasonable that clinically stable patients admitted to the ward using DOAC or AVK continue their anticoagulant treatment during ward hospitalization if there is no relevant drug–drug interaction between the anticoagulant and the medications used to treat COVID-19. We recommend switching DOAC and AVK to LMWH if the patient is admitted to the ICU or is at risk for a significant drug–drug interaction.

---

**Table 3 – Therapeutic dose of LMWH, UFH and fondaparinux and adjustments, according to body weight and renal function.**

<table>
<thead>
<tr>
<th>Therapeutic dose</th>
<th>Body weight</th>
<th>Chronic kidney disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enoxaparin</td>
<td>1 mg/kg SC twice daily</td>
<td>CrCl 15–29 mL/min: 1 mg/kg daily or UFH</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nadroparin</td>
<td>&lt;50 kg: 3800 IU SC twice daily</td>
<td>CrCl &lt; 15 mL/min: avoid, consider UFH</td>
</tr>
<tr>
<td></td>
<td>50–59 kg: 4750 IU SC twice daily</td>
<td>CrCl 30–50 mL/min: Give 25% of the dose</td>
</tr>
<tr>
<td></td>
<td>60–69 kg: 5700 IU SC twice daily</td>
<td>CrCl &lt; 30 mL/min: contraindicated</td>
</tr>
<tr>
<td></td>
<td>70–79 kg: 6650 IU SC twice daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;80–89 kg: 7600 IU SC twice daily</td>
<td></td>
</tr>
<tr>
<td>Dalteparin</td>
<td>200 IU/kg SC daily in the first 30 days, then 150 IU/kg SC daily until end of treatment</td>
<td>Dose must be adjusted according to anti-FXa activity with a target of 0.5–1.5 IU/mL</td>
</tr>
<tr>
<td></td>
<td>(maximum dose is 18,000 IU per day)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dose should be reduced by 17–33%, if platelet count &lt; 100 × 10^9/L</td>
<td></td>
</tr>
<tr>
<td>Bemiparin</td>
<td>115 IU/kg SC daily</td>
<td>CrCl = 30 mL/min: contraindicated</td>
</tr>
<tr>
<td>Tinzaparin</td>
<td>175 IU/kg SC daily</td>
<td>CrCl &lt; 20 mL/min: contraindicated</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>&lt;50 kg: 5 mg SC daily</td>
<td>CrCl &lt; 30 mL/min: contraindicated</td>
</tr>
<tr>
<td></td>
<td>&gt;100 kg: 7.5 mg SC daily</td>
<td></td>
</tr>
<tr>
<td>UFH</td>
<td>Loading dose: 80 IU/kg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maintenance dose: 18 IU/kg/h continuous infusion</td>
<td></td>
</tr>
</tbody>
</table>

LMWH: low molecular weight heparin; UFH: unfractionated heparin; BMI: body mass index; SC: subcutaneous; CrCl: creatinine clearance; IU: international unit.

---

**Summary of the recommendations**

The analysis of the peripheral blood smear, platelet count, PT, aPTT, fibrinogen and D-dimer levels are recommended for all hospitalized patients at admission. These parameters should be regularly monitored in critically ill patients. The most adequate time interval between tests is uncertain and testing should be based on clinical indication, assays availability and the local laboratory capacity and facility.

We suggest performing venous compression Duplex scan at admission of ICU patients and then on a regular basis, whenever available and at convenient intervals, to detect DVT and to prevent its complications. We also suggest maintaining vigilance for clinical and echocardiographic signs of PE.

The diagnosis of DIC does not indicate anticoagulation, unless a thrombotic event is present. The use of
Anticoagulants in COVID-19 should be restricted to prophylaxis of VTE or the treatment of thrombotic events.

All patients hospitalized for suspected or confirmed COVID-19 should receive pharmacologic thromboprophylaxis, unless there are contraindications (Table 1). We suggest the use of LMWH. Alternatively, UFH or fondaparinux can be given for thromboprophylaxis. In the case that pharmacologic thromboprophylaxis is contraindicated, mechanical prophylaxis should be used.

We suggest the use of LMWH at a standard dose for thromboprophylaxis, adjusted for body weight and renal function (Table 2), for patients admitted to general wards or the ICU, unless there are specific contraindications (Table 1). We are aware that the apparent increased incidence of VTE in COVID-19 has led physicians to change their practice by increasing the dose of prophylactic anticoagulation to intermediate or therapeutic doses of LMWH in ICU patients or in patients with high D-dimers or fibrinogen levels. However, the benefit of this approach has not yet been confirmed and trials are needed to address this question.

Prophylaxis for thrombosis should be prescribed during the entire hospitalization period. It is reasonable to maintain prophylaxis after the hospital discharge for patients at high risk of thrombosis or for those with immobility, unless there are specific contraindications. The risks and benefits of this approach should be reevaluated periodically.

Acute VTE events should be confirmed by imaging tests. In the case this is not feasible, presumptive diagnosis of an acute VTE event may be made based on clinical history, combined with physical examination, laboratory and other available tests. The diagnosis of VTE should not be based solely on the values of D-dimers.

We recommend the use of LMWH for the treatment of acute VTE. Alternatively, UFH or fondaparinux can be used (Table 3).

We recommend switching DOAC and AVK to LMWH if the patient is admitted to the ICU or is at risk of significant drug–drug interaction.

Conflicts of interest:

FOS is on speaker’s bureau for Bayer.

MCC is a consultant/advisor for Sanofi-Aventis on VTE prophylaxis.

AVSM is a consultant/advisor for Pfizer, Bayer, Novartis, Daiichi-Sankyo, Zodiac and Roche.

ATR is on speaker’s bureau for Bayer, Boehringer and Pfizer.

ATR is a consultant/advisor for Pfizer and Sanofi.

ER is on speaker’s bureau for Bayer, BMS/PFE, Aspen, BI, Daiichi Sankyo. ER is a consultant/advisor for Pfizer, BMS, Bayer, Sanofi, Amgen, Daiichi-Sankyo, Cristalia and Aspen.

JAB is on speaker’s bureau for Pfizer, Bayer, Daiichi-Sankyo and Sanofi.

DML is on speaker’s bureau for Bayer, Stago, Daiichi Sankyo, Novartis and Sanofi.

CCF is on speaker’s bureau for Bayer.

The remaining authors declare no conflict of interest.

REFERENCES


